ISouth Africa Delivery, iDaily Domestic Delivery, I-European Domestic Delivery

I-Monomethyl auristatin E (MMAE) ipowder

Akukho kalo
5.00 ngaphandle kwe 5 ngenxa ye 1 ireyithingi abathengi
SKU: 474645-27-7. Udidi:

I-AASraw iqukumbela kunye nokukwazi ukuvelisa kwigram ukuya kwi-Monometerhyl auristatin E (MMAE) i powder (474645-27-7), phantsi komgaqo weCGMP kunye nolawulo lwekhwalithi ephezulu.

Ingcaciso yeMveliso

I-Monomethyl auristatin E (MMAE) ividiyo ye powder


I-Monomethyl auristatin E (MMAE) ipowder Abalinganiswa basisiseko

igama: I-Monomethyl auristatin E (MMAE) ipowder
CAS: 474645-27-7
I-molecular Formula: C39H67N5O7
Isisindo somzimba: 717.97858
Melt Point: 238-240 ° C
Isitoreji sokugcina: Gcina kwisitya sokuqala, phakathi kwe-36 ukuya kwi-46 degrees F
umbala: Powder


I-Monomethyl auristatin E powder njenge-agent ye-antimitotic

Amagama

I-Brentuximab vedotin, i-MMAE powder

I-Monomethyl auristatin I-E powder Usage

• Abantu abadala
I-Monotherapy, i-1.8 mg / kg (ukuba ungadluli i-180 mg / umthamo) IV nganye kwiiveki ze-3; kunye ne-chemotherapy, i-1.2 mg / kg (ukuba ungadluli i-120 mg / umthamo) IV nganye kwiiveki ze-2.

• Amayeza
I-Monotherapy, i-1.8 mg / kg (ukuba ungadluli i-180 mg / umthamo) IV nganye kwiiveki ze-3; kunye ne-chemotherapy, i-1.2 mg / kg (ukuba ungadluli i-120 mg / umthamo) IV nganye kwiiveki ze-2.

I-Monomethyl auristatin E powder (i-MMAE powder, i-vedotin) i-agent e-antimitotic enamandla kakhulu evimbela isahlulo seseli ngokuthintela i-polymerization ye-tubulin. Iintsapho ze-auristatines zifana neemveliso zesimo semvelo esiyi-Dolastatin 10, i-ultrapotent cytotoxic microtubule inhibitors ezisetyenziswe njengokuhlawulwa kweelayisti kuma-conjugates e-anti-drug conjugates. I-Monomethyl auristatin E powder okanye i-MMAE powder i-100-1000 amaxesha angaphezu kwe-doxorubicin (i-Adriamycin / i-Rubex) kwaye ayikwazi ukusetyenziswa njengeziyobisi ngokwazo. Nangona kunjalo, njengenxalenye ye-antiju-drug conjugate okanye i-ADC, i-MMAE powder idibaniswa nomntu ongenamalungu omzimba (mAb) obona umgama othile kumakethi omhlaza kwaye uqondisa i-MMAE powder kwi-cell cell.

I-linker edibanisa i-MMAE powder kwi-anti-monoglonal antibody isigxina kwi-extracellular fluid, kodwa inamathele nge-cathepsin xa i-anti-drug-conjugate idibene nomhlaza wesigxina egciniweyo kwaye ingenayo iseli somhlaza, emva koko i-ADC ikhupha i-MMAE i powder kwaye isebenzise indlela enamandla yokulwa ne-mitotic. Izifo zogonyamelo lwe-Antibody-drug conjugates ziphucula iziphumo ze-antitumor ze-antibodies kunye nokunciphisa iziphumo ezimbi zenkqubo ye-cytotoxic.

Isilumkiso kwi-Monomethyl auristatin E powder

• I-pneumonitis, isifo sepulmonary, isifo sokuphefumula kwesifo
Isifo esinobungozi obungasetshenziswanga (umz., I-pneumonitis, isifo se-pulmary disease, i-acute respiratory syndrome). ezinye iimeko zazibulala. Gcina izigulane ngeempawu kunye neempawu zetyhefu zepulmoni ezifana nokukhwehlela kunye ne-dyspnea. Hlola izigulane eziphuhlisa iimpawu ezintsha zeempommon; ubambe i-brentuximab de iimpawu ziphucule. Ukusetyenziswa okuhambisanayo kwe-brentuximab ene-bleomycin ene-chemotherapy (ngaphandle kwelebuli), njenge-ABVD (adriamycin, bleomycin, vinblastine, i-dacarbazine), iyaphikiswa ngenxa yengozi yokwanda kwe-pulmonary toxicity. Ukungena ngaphakathi kunye / okanye ukuvuvukala (kufumaneka kwi-X-ray esifubeni okanye ukucatshulwa kwetekisi ecatshulwayo) kwenzeka kaninzi kwii-Hodgkin izigulane ze-lymphoma ezifumana i-brentuximab kunye ne-ABVD kwilingo lonyango xa kuthelekiswa nezigulane zokulawula iziganeko ezafumana i-ABVD yodwa. Uninzi lweemeko zichongiwe emva kweyonyango ye-corticosteroid.

I-peripheral neuropathy
I-peripheral neuropathy, ngokuyinhloko ye-sensory neuropathy, ibikwe nge-brentuximab i-vedotin yonyango; I-peripheral neuropathy iyimfuneko. Gcina izigulane ngeempawu ze-neuropathy (umz., U-hypoesthesia, i-hyperesthesia, i-paresthesia, ukungathandeki, ukuvutha komlilo, ubuhlungu bentliziyo, okanye ubuthathaka). Ukuphazamiseka kolwaphulo, ukunciphisa umlinganiselo, okanye ukuyeka ukuhlawulela, kunokufuneka kwizigulane ezenza uphando olutsha okanye olwenyukayo lwe-peripheral neuropathy.

• I-anemia, i-geriatric, i-neutropenia, i-thrombocytopenia
Ubuthakathaka obuninzi be-hematologic toxicities (umzekelo, i-anemia, thrombocytopenia, i-neutropenia) kunye neziganeko ezibulalayo nezibi kakhulu ze-febrile neutropenia ziye zabikwa nge-brentuximab i-vedotin yonyango; i-neutropenia inokuhlala ide (i-1 iveki okanye ixesha elide). Izigulane ezinobunzima abaneminyaka eyi-65 ubudala nangaphezulu kunye neHodgkin lymphoma abafumene i-brentuximab vedotin kunye kunye ne-chemotherapy bafumana amazinga aphezulu e-febrile neutropenia xa kuthelekiswa nezigulane ezincinci. Fumana igalelo elipheleleyo legazi ngaphambi kokuba nganye i-brentuximab dose kwaye kaninzi xa i-3 okanye i-4 neutropenia yenzeka; iliso zonke izigulane ngenxa yomkhuhlane. Ukuphazamiseka kolwaphulo, ukunciphisa umlinganiselo, okanye ukuyeka ukunyuka, kunokufuneka kwizigulane eziphuhlisa ibakala le-3 okanye i-4 neutropenia; qwa lasela ukongezwa kweprogramlactic granulocyte-colony factor stimulating factor (G-CSF) kunye namanani alandelayo. Ukulawula i-G-CSF ngokuqala ngomjikelezo we-1 kwizigulane ezifumana i-brentuximab vedotin ngokudibanisa ne-chemotherapy.

• I-tumor lysis syndrome (TLS)
I-tumor lysis syndrome (TLS) ibixelwe kwizigulane ezitholwe i-brentuximab vedotin. Izigulane ezinezicubu ezandayo ngokukhawuleza kunye / okanye umthwalo ophezulu we-tumor unokuba neengozi yokwanda kwe-TLS. Gcina izigulane ngeempawu ze-TLS (umzekelo, i-serum electrolytes, uric acid, i-serum creatinine) ngaphambi nangethuba lokunyanga; ukumisela iprophylactic efanelekileyo kunye nonyango (umzekelo, i-hydration, i-uric acid yokunciphisa unyango) njengoko kuyimfuneko.

• Inkqubela ye-leukoencephalopathy
Iziganeko ezibulalayo ze-letifencephaphaphapathy (PML) ye-multifocal leukoencephalopathy (i-PML), eyenziwa yi-John Cunningham virus (i-JC virus), kuye kwabikwa nge-brentuximab therapy; ezinye iimeko zenzeka kwiinyanga zokuqala ze-3 zokuqala unyango. Izigulane ezinezonyango zangaphambili zokuzikhusela okanye izifo ezingagqithisi umzimba zingangobungozi obuninzi bokusuleleka kwintsholongwane ye-JC kunye ne-PML. Ukuphonononga izigulane eziphuhlisa iindlela ezintsha zeengqondo, iingcamango okanye iimpawu kunye neempawu ezifana nokutshintsha kwimiqondo okanye ukuziphatha; udideko; ukukhubazeka kwememori; utshintsho kwimboniso, inkulumo, okanye ukuhamba; kunye / okanye ukunciphisa amandla okanye ubuthathaka kwelinye icala lomzimba. Gcina unyango xa i-PML ikhunjulwa; ukuyeka i-brentuximab kwizigulane eziqinisekisiweyo ze-PML.

• Ukukhubazeka komnxeba
Gwema ukusebenzisa i-brentuximab vedotin kwizigulane ezinobungozi obunzima be-renal (imvume ye-creatinine (CrCl) ngaphantsi kwe-30 mL / min). Iziganeko zeBakala 3 okanye iziganeko ezimbi eziphezulu kunye nokufa kwaba ngaphezulu kwizigulane ezinobungozi obunzima bokuqhathaniswa nokuqhathaniswa nokuxhatshazwa kwezilwanyana eziqhelekileyo (i-CrCl enkulu kune-80 mL / min) kwisifundo esincinane se-pharmacokinetic.

• Isifo esiphezulu
Gwema ukusetyenziswa kwe-brentuximab vedotin kwizigulane ezine-moderation (Child-Pugh B) okanye ezinzima (Child-Pugh C) isifo esiyingozi / ukukhubazeka; i-dose yokuqala eyancitshiswayo icetyiswa kwizigulane ezinobungozi obunzima be-hepatic (Child-Pugh A). Iziganeko zeBakala 3 okanye iziganeko ezichasayo kunye nokufa kwaba phezulu kwizigulane ezinokukhubazeka okuthe ngqo okanye eziqatha kakhulu xa zithelekiswa nezigulane ezinomsebenzi oqhelekileyo we-hepatic kwi-small-dose-pharmacokinetic study. I-hepatotoxicity (umzekelo, ukulimala kwe-hepatocellular, i-enzyme ephezulu ye-hepatic, kunye ne-hyperbilirubinemia) kuye kwabikwa nge-brentuximab i-vedotin unyango. Ezinye iziganeko zenzeke emva kwesosi sokuqala okanye kwi-rechallenge yeziyobisi; Kuye kwaxelwa ukufa okuhlobene ne-hepatotoxicity. Ukubeka iliso ukuhlolwa kwesibindi (i-LFTs), kubandakanya i-bilirubin, ngaphambi nangesikhathi sonyango. Ukuphazamiseka kolwaphulo, ukunciphisa umlinganiselo, okanye ukuyeka ukuhlawulela, kunokufuneka kwizigulane ezenza uphuhliso olutsha, olwenyukayo, okanye oluphindaphindiweyo lwe-hepatotoxicity. Izigulane ezinezifo ze-hepatic ezikhoyo ngaphambili okanye i-LFTs eziphakamileyo kwinqanaba kunye nezigulane ezithobela amayeza adibeneyo zingabangela umngcipheko wokwanda kwe-hepatotoxicity.
• Ukugula, isispsi
Izifo ezikhuselekileyo kunye nezinye izifo ezikhuselekileyo, kubandakanya i-pneumonia, i-bacteria, kunye ne-sepsis (ezinye iimeko ezibulalayo), ziye zaxelwa nge-brentuximab yonyango lwe-vedotin. Hlola ngokukhawuleza izigulane ngexesha lotyando lweempawu kunye neempawu ze-bacterial, fungal, okanye intsholongwane ye-virus.

• Impendulo echaphazelekayo
Ukuphendula okuxhomekeke kumxube kubandakanya i-anaphylaxis kuye kwaxelwa nge-brentuximab i-vedotin yonyango; Ngoko ke, jongana nezigulane zivalele iimpawu zempendulo ngexesha lokungeniswa kwe-brentuximab. Ngokukhawuleza kwaye unqunywe ngokusisigxina unyango ukuba i-anaphylaxis ivela. Yeka ukunyuswa kunye nokusekela ulawulo olufanelekileyo lwezonyango kwizigulana eziphuhlisa ukuphendula okuxhomekeke ku-infusion. Ukucetyiswa (umzekelo, i-acetaminophen, i-antihistamine, kunye / okanye i-corticosteroid) ngaphambi kokunyanzeliswa kwezigulana ezithe zafumana ukuphendula kwangaphakathi kwe-infusion.

• I-colitis, i-GI yegazi, isifo se-GI, isithintelo se-GI, ukuphazamiseka kwe-GI, i-ileus, isifo sesilonda sezilonda
Iingxaki ezinzulu zesisu (GI) ezibandakanya i-GI perforation, ukuphuma kweGI, ukuguguleka kwe-GI, isifo sesilonda se-peptic, isithintelo se-GI, i-neutropenic colitis, i-enterocolitis kunye neyeus zibikwe nge-brentuximab i-vedotin yonyango; Ezinye iziganeko zabangela ukufa. Hlola ngokukhawuleza kwaye uphathe iingxaki ze-GI kwizigulana ezenza iimpawu ezintsha ze-GI okanye ezona zimbi. Sebenzisa i-brentuximab ngokuqaphela kwizigulane ezineembali zesifo se-GI. Izigulane ezinembali ye-lymphoma kunye nokubandakanyeka kwe-GI inokuba yingozi enkulu yokwenyuka kwe-GI.

• Ukukhulelwa
I-Brentuximab i-vedotin inokubangela ingozi yomntwana xa ikhulelwe ngexesha lokukhulelwa ngokusekelwe kwindlela yokusebenza kunye nedatha kwizifundo zezilwanyana. Abafazi besakhono sokuzalana kufuneka bacebise ukuba bangazikhulelwa ngelixa befumana i-brentuximab. Ukuba ibhinqa likhulelwa ngeli xesha lithatha le michiza, kufuneka ifundwe ngengozi enokubakho emntwaneni. Kwizifundo zezilwanyana, i-embryo-fetal-toxicities eziquka ukungabikho kokuzalwa komzimba zagqalwa kwii-brentuximab izidakamizwa ezibangele ukuboniswa komama okwakuboniswa nokugqithiswa kwabantu kwi-dose ephakanyisiweyo.

• Imfuno yokukhulelwa, ukungabikho komntwana, ukuxilongwa kwamadoda, ukuvavanya ukukhulelwa, ingozi yokuzala
Izigulane zeengcebiso malunga nomngcipheko wokuzala nokukhulelwa kwexesha lokukhusela ngexesha le-brentuximab vedotin. Uvavanyo lokukhulelwa kufuneka lwenziwa ngaphambi kokuqala i-brentuximab kwizigulane zentombi zobuncwane bokuzala. Ezi gulane kufuneka zisebenzise ukukhulelwa kwangaphambili kwaye ziphephe ukukhulelwa ngexesha kwaye ubuncinane kweenyanga ze-6 emva kokunyanga kwe-brentuximab. Abasetyhini abakhulelweyo ngelixa befumana i-brentuximab kufuneka bafundwe ngengozi ebonakalayo kumntwana. Ukongezelela, izigulane zesilisa ezineqabane lamabhinqa elinokubakho ukuzala kufuneka zisebenzise ukukhulelwa kwangaphambili ngexesha lokunyanga kwaye ubuncinane ubuncinane beenyanga ze-6 emva kokunyangwa ngenxa yengozi yombutho wokuxhaswa kwamadoda. Ngokusekelwe kwizifundo zezilwanyana, i-brentuximab ingabangela ukungabikho kwamadoda kwindoda.

• Ukuncelisa isisu
Akukho nkcazelo ekhoyo malunga nobukho be-brentuximab vedotin ebisi loluntu, umphumo kwintsana enyancinci, okanye umphumo kwimveliso yobisi. Ngenxa yempembelelo engathandekiyo kumntwana onesibeleko (umz., I-cytopenias kunye neyolologic okanye isisu esiswini), ukuxeliswa kakubi akukhuthazwa ngexesha lokunyanga kwe-brentuximab. Cinga ngeenzuzo zokuncelisa, ukubeka ingozi yokufumaneka kweziyobisi zentsana, kunye nomngcipheko weimeko ezingaphathekiyo okanye ezingafanelekanga. Ukuba umntwana osondezayo ufumana impembelelo echaphazelekayo enxulumene neziyobisi ezilawulwa ngumama, ababoneleli bezempilo bayakhuthazwa ukuba babike impembelelo embi kwi-FDA.

I mi yalelo

I-Monomethyl auristatin I-E powder (i-MMAE powder) ikhutshwe ngokufanelekileyo kwi-SGN-35 ngaphakathi kweeseli ze-CD30 + zegazi kwaye, ngenxa yobunzima bayo, iyakwazi ukwenza umsebenzi we-cytotoxic kwiiseli zokulinda. I-MMAE i-powder ikhuthaza amangqamuzana omhlaza we-pancreatic kunye ne-IR kwishedyuli kunye nokuxhomekeka kwenzalo ehambelana nokuboshwa kwe-mitotic. I-Radiosensitization ibonakaliswa ngokusinda kwe-clonogenic nokunyuka kwama-DNA aphindwe kabini kwiiseli ezixilisiweyo.

I-Monomethyl auristatin E I-Raw Powder

I-10grams encinci.
Uphando malunga nobukhulu obuqhelekileyo (ngaphakathi kwe-1kg) lungathunyelwa kwiiyure ze-12 emva kokuhlawula.
Ukwenza umlinganiselo omkhulu (ngaphakathi kwe-1kg) ungathunyelwa kwimihla yokusebenza ye-3 emva kokuhlawula.

I-Monomethyl auristatin E I-Raw Powder Recipes

Ukubuza ummeli wethu ummeli (Representative Representative) (CSR) ngeenkcukacha, ngokubhekiselele kuyo.

I-Monomethyl auristatin I-E powder Marketing

Ukubonelelwa kwikamva elizayo.


IV. Indlela yokuthenga i-Monomethyl auristatin E powder; ukuthenga i-MMAE powder kwi-AASraw?

1.Qhagamshelana nathi nge-imeyile yethu inkqubo yophando, okanye i-skype ye-intanethiummeli wenkonzo yamakhasimende (CSR).
2.Ukusibonelela ngobuninzi bakho kunye neadesi.
I-3.I-CSR yethu iya kukunika isingeniso, ixesha lokuhlawula, inombolo yokulandelela, iindlela zokuhambisa kunye nomhla wokufika oqikelelwayo (i-ETA).
I-4.Inkokhelo eyenziwe kwaye iimpahla ziya kuthunyelwa kwiiyure ze-12 (Ukuze ulandelwe ngaphakathi kwe-10kg).
5.Goods zifunyenwe kwaye zinike izimvo.


=

IAAA

I-COA 474645-27-7 I-Monomethyl auristatin E (MMAE) I-AASRAW

HNMR

Siyi-monomethyl auristatin e powder supplie, i-MMAE ipowder for sale, i-Monomethyl auristatin E (MMAE) powder (474645-27-7) ≥98% | AASraw

Recipes

I-Monomethyl auristatin E iRaw Powder Recipes:

Ukubuza ummeli wethu ummeli (Representative Representative) (CSR) ngeenkcukacha, ngokubhekiselele kuyo.

Iziqulatho kunye nokuqulunqwa kwemveliso

I-Antineoplastic Agent Monomethyl auristatin E (MMAE)

ngokutsha 1 ngenxa I-Monomethyl auristatin E (MMAE) ipowder

  1. ikaliwe 5 ngaphandle 5

    Aasraw -

    I-Monomethyl auristatin E (MMAE) i powder iyinhlakanipho

Yongeza kwakhona

Idilesi yakho ye email aziyi kupapashwa. amasimi ezifunekayo ziphawulwa *